Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis
Aim
COVID-19 clinical presentation is heterogeneous, ranging from asymptomatic to severe cases. While there are a number of early publications relating to risk factors for COVID-19 infection, low sample size and heterogeneity in study design impacted consolidation of early findings. There is a pressing need to identify the factors which predispose patients to severe cases of COVID-19. For rapid and widespread risk stratification, these factors should be easily obtainable, inexpensive, and avoid invasive clinical procedures. The aim of our study is to fill this knowledge gap by systematically mapping all the available evidence on the association of various clinical, demographic, and lifestyle variables with the risk of specific adverse outcomes in patients with COVID-19.
Methods
The systematic review was conducted using standardized methodology, searching two electronic databases (PubMed and SCOPUS) for relevant literature published between 1st January 2020 and 9th July 2020. Included studies reported characteristics of patients with COVID-19 while reporting outcomes relating to disease severity. In the case of sufficient comparable data, meta-analyses were conducted to estimate risk of each variable.
Results
Seventy-six studies were identified, with a total of 17,860,001 patients across 14 countries. The studies were highly heterogeneous in terms of the sample under study, outcomes, and risk measures reported. A large number of risk factors were presented for COVID-19. Commonly reported variables for adverse outcome from COVID-19 comprised patient characteristics, including age >75 (OR: 2.65, 95% CI: 1.81–3.90), male sex (OR: 2.05, 95% CI: 1.39–3.04) and severe obesity (OR: 2.57, 95% CI: 1.31–5.05). Active cancer (OR: 1.46, 95% CI: 1.04–2.04) was associated with increased risk of severe outcome. A number of common symptoms and vital measures (respiratory rate and SpO2) also suggested elevated risk profiles.
Conclusions
Based on the findings of this study, a range of easily assessed parameters are valuable to predict elevated risk of severe illness and mortality as a result of COVID-19, including patient characteristics and detailed comorbidities, alongside the novel inclusion of real-time symptoms and vital measurements.
Top-30
Journals
|
5
10
15
20
|
|
|
PLoS ONE
20 publications, 4.56%
|
|
|
Vaccines
18 publications, 4.1%
|
|
|
Frontiers in Immunology
9 publications, 2.05%
|
|
|
Scientific Reports
9 publications, 2.05%
|
|
|
Viruses
8 publications, 1.82%
|
|
|
F1000Research
7 publications, 1.59%
|
|
|
International Journal of Environmental Research and Public Health
7 publications, 1.59%
|
|
|
Journal of Clinical Medicine
6 publications, 1.37%
|
|
|
BMJ Open
5 publications, 1.14%
|
|
|
Biomedicines
4 publications, 0.91%
|
|
|
Journal of Personalized Medicine
4 publications, 0.91%
|
|
|
Vaccine
4 publications, 0.91%
|
|
|
Frontiers in Public Health
4 publications, 0.91%
|
|
|
Nutrients
3 publications, 0.68%
|
|
|
Infection
3 publications, 0.68%
|
|
|
Immunity and Ageing
3 publications, 0.68%
|
|
|
BMC Geriatrics
3 publications, 0.68%
|
|
|
BMC Infectious Diseases
3 publications, 0.68%
|
|
|
Cureus
3 publications, 0.68%
|
|
|
Cochrane Database of Systematic Reviews
3 publications, 0.68%
|
|
|
Journal of Medical Virology
3 publications, 0.68%
|
|
|
Microorganisms
3 publications, 0.68%
|
|
|
European Respiratory Review
2 publications, 0.46%
|
|
|
New England Journal of Medicine
2 publications, 0.46%
|
|
|
Cancers
2 publications, 0.46%
|
|
|
Frontiers in Cellular and Infection Microbiology
2 publications, 0.46%
|
|
|
Pathogens
2 publications, 0.46%
|
|
|
Nature Immunology
2 publications, 0.46%
|
|
|
Nature Communications
2 publications, 0.46%
|
|
|
5
10
15
20
|
Publishers
|
10
20
30
40
50
60
70
80
|
|
|
MDPI
79 publications, 18%
|
|
|
Springer Nature
77 publications, 17.54%
|
|
|
Elsevier
60 publications, 13.67%
|
|
|
Cold Spring Harbor Laboratory
33 publications, 7.52%
|
|
|
Wiley
25 publications, 5.69%
|
|
|
Public Library of Science (PLoS)
24 publications, 5.47%
|
|
|
Frontiers Media S.A.
21 publications, 4.78%
|
|
|
Taylor & Francis
10 publications, 2.28%
|
|
|
BMJ
9 publications, 2.05%
|
|
|
F1000 Research
8 publications, 1.82%
|
|
|
Oxford University Press
8 publications, 1.82%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
8 publications, 1.82%
|
|
|
SAGE
7 publications, 1.59%
|
|
|
JMIR Publications
6 publications, 1.37%
|
|
|
Bentham Science Publishers Ltd.
6 publications, 1.37%
|
|
|
Georg Thieme Verlag KG
4 publications, 0.91%
|
|
|
European Respiratory Society (ERS)
3 publications, 0.68%
|
|
|
Institute of Electrical and Electronics Engineers (IEEE)
3 publications, 0.68%
|
|
|
XMLink
3 publications, 0.68%
|
|
|
Research Square Platform LLC
3 publications, 0.68%
|
|
|
Massachusetts Medical Society
2 publications, 0.46%
|
|
|
Baishideng Publishing Group
2 publications, 0.46%
|
|
|
PAGEPress Publications
2 publications, 0.46%
|
|
|
Cambridge University Press
2 publications, 0.46%
|
|
|
Canadian Science Publishing
1 publication, 0.23%
|
|
|
Mary Ann Liebert
1 publication, 0.23%
|
|
|
Radiological Society of North America (RSNA)
1 publication, 0.23%
|
|
|
AOSIS
1 publication, 0.23%
|
|
|
Annual Reviews
1 publication, 0.23%
|
|
|
10
20
30
40
50
60
70
80
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.